

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6435381

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
VIVA BIOTECH (SHANGHAI) LTD.	05/18/2018
RECEIVING PARTY DATA	
Name:	AGIOS PHARMACEUTICALS, INC.
Street Address:	88 SIDNEY STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17000411
CORRESPONDENCE DATA	
Fax Number:	(215)568-3439
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2155683100
Email:	patents@bakerlaw.com
Correspondent Name:	BAKERHOSTETLER
Address Line 1:	CIRA CENTRE, 12TH FLOOR
Address Line 2:	2929 ARCH STREET
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19104
ATTORNEY DOCKET NUMBER:	116605.000195
NAME OF SUBMITTER:	GINA CLAUSZ
SIGNATURE:	/Gina Clausz/
DATE SIGNED:	12/07/2020
Total Attachments: 3	
source=116605-000195_ExecutedAssignment_VivaBiotechToAgiostPharmaceuticals#page1.tif	
source=116605-000195_ExecutedAssignment_VivaBiotechToAgiostPharmaceuticals#page2.tif	
source=116605-000195_ExecutedAssignment_VivaBiotechToAgiostPharmaceuticals#page3.tif	

ASSIGNMENT

For good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, **Viva Biotech (Shanghai) Ltd**, a Chinese company having a place of business at **334 Aidisheng Road, ZhangJiang High-Tech Park, Shanghai 201203, China**, its successors, assigns and legal representatives (hereinafter the "Undersigned"), do hereby irrevocably and unconditionally:

CONVEY, ASSIGN AND TRANSFER to **Agios Pharmaceuticals, Inc.**, a Delaware corporation having a place of business at **88 Sidney Street, Cambridge, Massachusetts 02139, United States of America**, its successors, assigns and legal representatives (collectively hereinafter the "Assignee"), the Undersigned's entire right, title and interest throughout the world in the inventions and improvements which are subject of an application for the United States Patent entitled **INHIBITORS OF CELLULAR METABOLIC PROCESSES**, filed **August 30, 2017**, and assigned U.S. Serial Number **15/691,408**, including:

the inventions disclosed in the above-identified application(s);

such application(s), and all divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other applications for a patent or patents which have been or shall be filed in the United States (including without limitation International Patent Application No. PCT/CN2016/097524, filed August 31, 2016 and entitled **INHIBITORS OF CELLULAR METABOLIC PROCESSES**; and U.S. Provisional Application No. 62/548,738, filed August 22, 2017, and entitled **INHIBITORS OF CELLULAR METABOLIC PROCESSES**), and in all foreign countries and jurisdictions based in whole or in part on any of the said inventions and improvements (including any application for a utility model, design registration(s), and inventor's certificate(s));

the right to claim priority to the above-identified application(s) in relation to subject matter based in whole or in part on the above-identified application(s) and any of the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes;

the right to file in my name or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventor's certificate(s) for said inventions and improvements in the United States and all foreign countries under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and

the right to all causes of action, remedies, and other enforcement rights related to the above-identified application(s), including without limitation the right to sue for past, present, or future infringement, misappropriation, or violation of any and all rights related to the above-identified application(s) and any of the foregoing, including the right to obtain and collect damages for past, present, or future infringement.

The Undersigned authorizes and requests the U.S. and foreign patent issuing authority to issue any and all United States and foreign patents (including any application for a utility model, design registrations, and inventor's certificate(s)) on the said inventions and improvements to the Assignee.

The Undersigned covenants, that when requested and at the reasonable expense of the Assignee, in order to carry out in good faith the intent and purpose of this Assignment, the Undersigned shall (1) execute all provisional, non-provisional, divisional, continuing (including continuation-in-part), substitute, renewal, reissue, and all other patent applications for the inventions and improvements which are subject of the said application(s), as the Assignee may reasonably request to effectuate fully this Assignment; (2) execute all rightful oaths, declarations, assignments, powers of attorney and other papers for the inventions and improvements which are subject of the said application(s); (3) communicate to the Assignee all facts known to the Undersigned relating to the inventions and improvements which are subject of the said application(s), and the history thereof; (4) cooperate with the Assignee in any interference, reexamination, reissue, opposition, dispute, or litigation involving any of the applications or patents for the inventions and improvements which are subject of the said application(s); and (5) take such further actions as the Assignee shall reasonably consider necessary or desirable for vesting title to the said inventions and improvements in the Assignee, or for securing, maintaining and enforcing proper patent protection for the said inventions and improvements.

The Undersigned covenants, that should the execution date, filing date and/or Application Number be not entered or be incorrect at the time the Undersigned executed this document, the Undersigned hereby authorizes and requests an attorney of Assignee to insert the information or make the correction.

IN TESTIMONY WHEREOF, I have executed this document on the date indicated below.

Undersigned: **Viva Biotech (Shanghai) Ltd**

5. 18. 2018
Date

[Signature]
Name:

Title:
Authorized Representative of Viva Biotech (Shanghai) Ltd

Witnessed by:

(1) [Signature]
Signature of Witness

5/18/2018
Date

Qinbo Huang
Print Witness Name

Shanghai, China
Witness' City and Country of Residence


(2) [Signature]
Signature of Witness

5/18/2018
Date

Shiyao Lu
Print Witness Name

Shanghai, China
Witness' City and Country of Residence

ACCEPTED AND AGREED TO BY ASSIGNEE: Agios Pharmaceuticals, Inc.:

Signature: 

Date: May 23, 2018

Printed Name: Mia Wang, Ph.D., J.D.

Title: SVP, General Counsel